People: BioSpecifics Technologies Corp. (BSTC.O)
BSTC.O on Consolidated Issue listed on NASDAQ Global Market
28.11USD
9 Feb 2010
28.11USD
9 Feb 2010
Price Change (% chg)
$-0.02 (-0.07%)
$-0.02 (-0.07%)
Prev Close
$28.11
$28.11
Open
--
--
Day's High
$28.75
$28.75
Day's Low
$28.00
$28.00
Volume
12,398
12,398
Avg. Vol
37,544
37,544
52-wk High
$33.00
$33.00
52-wk Low
$15.79
$15.79
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
| Wegman, Thomas | 54 | 2007 | President, Principal Executive Officer, Principal Financial Officer, Secretary, Director |
| Gitman, Paul | 68 | 1990 | Director |
| Morgan, Henry | 88 | 1990 | Director |
| Schamroth, Michael | 69 | 2004 | Director |
| Wegman, Toby | 74 | 2007 | Director |
| Wegman, Mark | 59 | 2007 | Director |
| Geller, Matthew | 60 | 2008 | Director |
Biographies
| Name | Description |
|---|---|
| Wegman, Thomas | Thomas L. Wegman is President, Principal Executive Officer, Principal Financial Officer, Secretary, Director of Biospecifics Technologies Corp. He has served as an officer of the Company for more than 15 years. He is current President and has served as President since October 17, 2005. Prior to such appointment he served as the executive vice president of the Company. Effective in 1994, Mr. Wegman became a director on the Board of the Company and has served as such since that time. He has over 30 years of experience in the bio-pharmaceutical industry that encompasses managing company operations and drug development, licensing, and registration. From 1978 thru 1983, Mr. Wegman managed the production, marketing and foreign registration activities related to an avian vaccine business. Mr. Wegman has been instrumental in licensing technologies from universities for use by the Company. He is the author of a number of U.S. and foreign patents in the life sciences field. Mr. Wegman received his B.A. from Boston University. |
| Gitman, Paul | Dr. Paul A. Gitman is currently a Director on the Board of Biospecifics Technologies Corp. and has served as a Director of the Company since 1990. He is board certified by the American Board of Internal Medicine and the American Board of Quality Assurance and Utilization Review. Following 25 years in private medical practice he joined the fulltime faculty of Long Island Jewish Medical Center where he became Medical Director. In 2007, Dr Gitman was promoted to Vice President of Medical Affairs for the North Shore Long Island Jewish Health system. Dr. Gitman is currently an Associate Professor of Medicine at Albert Einstein College of Medicine as well as the Vice Chairman of the Medical Society of the State of New York’s Committee for Physician’s Health. He has served on the New York State Board of Medicine for 10 years and on various New York State Committees and Task Forces. He is past President of both the New York Chapter of the American College of Physicians and the Medical Society of the County of Queens. Dr. Gitman received his medical degree from Boston University School of Medicine. |
| Morgan, Henry | Henry Morgan is currently a Director on the Board of Biospecifics Technologies Corp. and has served as a Director of the Company since 1990, with the exception of a few interim months. He has been a practicing attorney for more than 50 years. Prior to his work as an attorney, he was employed in the insurance industry as an auditor and agent. His law practice is in the defense of corporations and individuals for claims asserted against them that allege professional errors and omissions, defective products, insurance coverage issues and employment related disputes. Mr. Morgan is a member of the Essex County, New Jersey State and American Bar Associations, the International Association of Defense Counsel and the Defense Research Institute. He received his B.A. and J.D. degrees from Rutgers, The State University of New Jersey. |
| Schamroth, Michael | Mr. Schamroth is currently a Director on the Board of Biospecifics Technologies Corp. and has served as a Director of the Company since 2004. He has been a partner of M. Schamroth & Sons in New York City for the past 39 years. As a principal in this fourth-generation international diamond house, Mr. Schamroth has experience in dealing with all aspects of the trade, from manufacturing to sales. He has been a member of the Diamond Manufacturers and Importers Association since 1964, and has served on the Nominating and Building Committees of the Diamond Dealers Club. In addition, Mr. Schamroth has served as a member of the Board of South Nassau Communities Hospital since 1976, the Board of the Winthrop-South Nassau University Health System since 1993 and the Board of Sound Bank of North Carolina since 2002. He has been a member of the Miami University Business Advisory Board since 1984 and served as its Chairman from 1987-1988. He received his B.S. in Business from Miami University, Oxford, Ohio. |
| Wegman, Toby | Ms. Wegman is currently a Director on the Board of Biospecifics Technologies Corp. and has served as a Director of the Company since June 25, 2007. Ms. Wegman has had a range of business-related work experiences. For five years she owned and operated a women’s apparel business and prior to that managed a women’s retail clothing operation. She has also been actively involved in the management of Edwin H. Wegman’s business interests and finances for many years. Ms. Wegman is a member of the Lion of Judah, and a lifetime member of the National Council of Jewish Women and HADASSAH. |
| Wegman, Mark | Dr. Wegman is currently a Director on the Board of Biospecifics Technologies Corp. and has served as a Director of the Company since June 25, 2007. He joined International Business Machines (“IBM”) in 1975 where Dr. Wegman is currently Head of Computer Science with world wide responsibilities in IBM’s eight research laboratories. Dr. Wegman is recognized for his contributions to computer algorithms and compiler optimization that have deeply influenced many areas of computer science and practice. This work was recognized by the Special Interest Group On Programming Languages in 2006 with its Programming Languages Achievement Award. He recently was named as an IBM Fellow, which is IBM’s highest technical honor. Dr. Wegman is the author of over 30 publications in the field of Computer Science. Dr. Wegman received his doctorate in Computer Science from the University of California at Berkeley. |
| Geller, Matthew | Dr. Matthew Geller is currently a Director on the Board of BioSpecifics Technologies Corp. and has served as a Director of the Company since September 23, 2008. Dr. Geller also currently serves as president of Geller Biopharm, Inc., where he focuses on advisory relationships, mergers, acquisitions and sales of biotechnology companies and as registered representative with Reedland Securities, where he is engaged in financial transactions for health care companies. From 2006 to 2008, Dr. Geller served as the head of healthcare banking at Rodman and Renshaw, during which period the group that he managed was consistently ranked #1 on the Street for PIPES and registered direct financial raises for healthcare companies. From 1994 to 2005, Dr. Geller was a managing Director and Senior Biotechnology analyst at Oppenheimer and CIBC World Markets. In connection with these positions, Dr. Geller was named one of the best stock-pickers in biotechnology in the Wall Street Journal’s Best on the Street Analysts Survey, was selected by Institutional Investor magazine as a member of its All-Star Home-Run hitters research team and has been a member of the publication’s All-America Research team. He consistently had the #1 rating for client service. Dr. Geller is often quoted in industry and general press, including the Wall Street Journal, the New York Times, and has made frequent television appearances on CNBC, Bloomberg television and CNN. He has served as a consultant to venture capital firms, biotech companies and portfolio managers and analysts. Dr. Geller has also served as a professor at the University of California, Berkeley, Duke University and the University of Michigan, Ann Arbor. Dr. Geller earned his bachelors degree with advanced standing in mathematics from Yale University, his master’s degree in mathematics from the University of California, San Diego and his Ph.D. in computer science from the University of California, Berkeley |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
| Wegman, Thomas | 254,891 |
| Gitman, Paul | -- |
| Morgan, Henry | -- |
| Schamroth, Michael | -- |
| Wegman, Toby | -- |
| Wegman, Mark | -- |
| Geller, Matthew | -- |
As Of 30 Dec 2008
Options Compensation
| Name | Options | Value |
|---|---|---|
| Wegman, Thomas | 205,200 | 100,548 |
| Gitman, Paul | 0 | 0 |
| Morgan, Henry | 0 | 0 |
| Schamroth, Michael | 0 | 0 |
| Wegman, Toby | 0 | 0 |
| Wegman, Mark | 0 | 0 |
| Geller, Matthew | 0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
| MORGAN HENRY | 306 | $30.31 |
| MORGAN HENRY | 200 | $30.36 |
| MORGAN HENRY | 10,000 | $1.00 |
| MORGAN HENRY | 10,000 | $2.56 |
| MORGAN HENRY | 11,254 | $30.04 |
| WEGMAN TOBY | 100,000 | $30.00 |
| WEGMAN THOMAS L | 100,000 | $30.00 |
| EDWIN H WEGMAN UEO | 100,000 | $30.00 |
| WEGMAN THOMAS L | 50,000 | $1.88 |
| EDWIN H WEGMAN UEO | 100,000 | $24.00 |
| GITMAN PAUL A | 5,000 | $1.00 |
| WEGMAN THOMAS L | 100,000 | $24.00 |
| WEGMAN TOBY | 100,000 | $24.00 |
| GITMAN PAUL A | 5,000 | $28.28 |
| GITMAN PAUL A | 12,500 | $27.47 |
| GITMAN PAUL A | 5,480 | $26.72 |
| GITMAN PAUL A | 6,000 | $27.00 |
| GITMAN PAUL A | 6,000 | $2.56 |
| GITMAN PAUL A | 5,000 | $27.65 |
| GITMAN PAUL A | 5,000 | $1.00 |
| GITMAN PAUL A | 4,000 | $25.30 |
| GITMAN PAUL A | 4,000 | $2.56 |
| GITMAN PAUL A | 2,020 | $25.40 |
| WEGMAN THOMAS L | 20,000 | $3.00 |
| RA CAPITAL MANAGEMENT L L C | 15,058 | $19.47 |
© Copyright 2010 Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
